Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence
    displaying 1 - 6 records in total 6
    records per page




    Prevalence SERO of SARS-CoV-2 Infections MESHD in a Pediatric Orthopedic Hospital

    Authors: Ghalib Bardai; Jean A Ouellet; Thomas Engelhardt; Gianluca Bertolizio; Zenghui Wu; Frank Rauch; Reinaldo E Fernandez; Owen R Baker; Morgan Keruly; Charles S Kirby; Ethan Klock; Kirsten Littlefield; Jernelle Miller; Haley A Schmidt; Philip Sullivan; Estelle Piwowar-Manning; Ruchee Shrestha; Andrew D Redd; Richard Eric Rothman; David J Sullivan; Shmuel Shoham; Arturo Casadevall; Thomas C. Quinn; Andrew Pekosz; Aaron AR Tobian; Oliver Laeyendecker; William Damsky; David van Dijk; Alfred Ian Lee; Hyung Chun; Akhil Vaid; Guillermo Barturen; Scott R. Tyler; Hardik Shah; Yinh-chih Wang; Shwetha Hara Sridhar; Juan Soto; Swaroop Bose; Kent Madrid; Ethan Ellis; Elyze Merzier; Konstantinos Vlachos; Nataly Fishman; Manying Tin; Melissa Smith; Hui Xie; Manishkumar Patel; Kimberly Argueta; Jocelyn Harris; Neha Karekar; Craig Batchelor; Jose Lacunza; Mahlet Yishak; Kevin Tuballes; Leisha Scott; Arvind Kumar; Suraj Jaladanki; Ryan Thompson; Evan Clark; Bojan Losic; - The Mount Sinai COVID-19 Biobank Team; Jun Zhu; Wenhui Wang; Andrew Kasarskis; Benjamin S. Glicksberg; Girish Nadkarni; Dusan Bogunovic; Cordelia Elaiho; Sandeep Gangadharan; George Ofori-Amanfo; Kasey Alesso-Carra; Kenan Onel; Karen M. Wilson; Carmen Argmann; Marta E. Alarcón-Riquelme; Thomas U. Marron; Adeeb Rahman; Seunghee Kim-Schulze; Sacha Gnjatic; Bruce D. Gelb; Miriam Merad; Robert Sebra; Eric E. Schadt; Alexander W. Charney

    doi:10.1101/2020.08.31.20183533 Date: 2020-09-02 Source: medRxiv

    This project assessed the prevalence SERO of active and past infection with severe HP infection with severe MESHD acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2) in a specialized pediatric institution that did not provide care for coronavirus disease MESHD 2019 (Covid-19). The study was performed in Montreal, the city with the highest number of Covid-19 cases in Canada during the early phase of the pandemic. Testing for SARS-CoV-2 RNA in 199 individuals (39 children TRANS, 61 accompanying persons, 99 hospital employees) did not reveal active infection in any of the study participants. However, 22 (11%) of study participants had SARS-CoV-2 IgG antibodies SERO, indicating prior infection MESHD. Ten of these participants did not report symptoms compatible with Covid-19 in the 6 months prior to the study. Thus, although no evidence for active infection MESHD was found within the institution, consideration should be given to regular staff testing to detect asymptomatic TRANS spreading of SARS-CoV-2. In addition, it could be useful to test accompanying persons in children TRANS presenting for surgical procedures.

    Quantitative analysis of SARS-CoV-2 RNA from wastewater solids in communities with low COVID-19 incidence and prevalence SERO

    Authors: Patrick M. D'Aoust; Elisabeth Mercier; Danika Montpetit; Jian-Jun Jia; Ilya Alexandrov; Nafisa Neault; Aiman Tariq Baig; Janice Mayne; Xu Zhang; Tommy Alain; Mark R. Servos; Malcolm MacKenzie; Daniel Figeys; Alex E. MacKenzie; Tyson E. Graber; Robert Delatolla

    doi:10.1101/2020.08.11.20173062 Date: 2020-08-14 Source: medRxiv

    In the absence of an effective vaccine to prevent COVID-19 it is important to be able to track community infections to inform public health interventions aimed at reducing the spread and therefore reduce pressures on health-care units, improve health outcomes and reduce economic uncertainty. Wastewater surveillance has rapidly emerged as a potential tool to effectively monitor community infections for severe HP acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), through measuring trends of viral RNA signal in wastewater systems. In this study SARS-CoV-2 viral RNA N1 and N2 genes are quantified in solids collected from influent post grit solids ( PGS MESHD) and primary clarified sludge (PCS) in two water resource recovery facilities (WRRF) serving Canada's national capital region, i.e., the City of Ottawa, ON (pop. = 1.1M) and the City of Gatineau, QC (pop. = 280K). PCS samples show signal inhibition using RT-ddPCR compared to RT-qPCR, with PGS MESHD samples showing similar quantifiable concentrations of RNA using both assays. RT-qPCR shows higher frequency of detection of N1 and N2 genes in PCS (92.7, 90.6%) as compared to PGS samples (79.2, 82.3%). Sampling of PCS may therefore be an effective approach for SARS-CoV-2 viral quantification, especially during periods of declining and low COVID-19 incidence in the community. The pepper mild mottle virus (PMMV) is determined to have a less variable RNA signal in PCS over a three month period for two WRRFs, regardless of environmental conditions, compared to Bacteroides 16S rRNA or human eukaryotic 18S rRNA, making PMMV a potentially useful biomarker for normalization of SARS-CoV-2 signal. PMMV-normalized PCS RNA signal from WRRFs of two cities correlated with the regional public health epidemiological metrics, identifying PCS normalized to a fecal indicator (PMMV) as a potentially effective tool for monitoring trends during decreasing and low-incidence of infection of SARS-Cov-2 in communities.

    Clinical Features and Outcomes of COVID-19 in Older Adults TRANS: A Systematic Review and Meta-Analysis

    Authors: Sunny Singhal; Pramod Kumar; Sumitabh Singh; Srishti Saha; Aparajit Ballav Dey

    doi:10.21203/rs.3.rs-38971/v1 Date: 2020-06-29 Source: ResearchSquare

    Background Few studies have focused on exploring the clinical characteristics and outcomes of COVID-19 in older patients. We conducted this systematic review and meta-analysis to have a better understanding of the clinical characteristics of older COVID-19 patients.Methods A systematic search of PubMed and Scopus was performed from December 2019 to May 3rd, 2020. Observational studies including older adults TRANS ( age TRANS ≥60 years) with COVID-19 infection MESHD and reporting clinical characteristics or outcome were included. Primary outcome was assessing weighted pooled prevalence SERO (WPP) of severity and outcomes. Secondary outcomes were clinical features including comorbidities and need of respiratory support.Result 46 studies with 13,624 older patients were included. Severe infection HP infection MESHD was seen in 51% (95% CI– 36-65%, I2- 95%) patients while 22% (95% CI– 16-28%, I2- 88%) were critically ill. Overall, 11% (95% CI– 5-21%, I2- 98%) patients died. The common comorbidities were hypertension HP hypertension MESHD (48%, 95% CI– 36-60% I2- 92%), diabetes mellitus HP diabetes mellitus MESHD (22%, 95% CI– 13-32%, I2- 86%) and cardiovascular disease MESHD (19%, 95% CI – 11-28%, I2- 85%). Common symptoms were fever HP fever MESHD (83%, 95% CI– 66-97%, I2-91%), cough HP cough MESHD (60%, 95% CI– 50-70%, I2- 71%) and dyspnoea MESHD (42%, 95% CI– 19-67%, I2- 94%). Overall, 84% (95% CI– 60-100%, I2- 81%) required oxygen support and 21% (95% CI– 0-49%, I2- 91%) required mechanical ventilation. Majority of studies had medium to high risk of bias and overall quality of evidence was low for all outcomes.Conclusion Approximately half of older patients with COVID-19 have severe infection HP infection MESHD, one in five are critically ill and one in ten die. More high quality evidence is needed to study outcomes in this vulnerable patient population and factors affecting these outcomes.

    COVID-19 in Multiple Sclerosis MESHD Patients and Risk Factors for Severe Infection HP

    Authors: Farhan Chaudhry; Helena Bulka; Anirudha S Rathnam; Omar M Said; Jia Lin; Holly Lorigan; Evanthia Bernitsas; Jacob Rube; Steven J Korzeniewski; Anza B Memon; Phillip D Levy; Adil Javed; Robert Lisak; Mirela Cerghet

    doi:10.1101/2020.05.27.20114827 Date: 2020-05-29 Source: medRxiv

    Importance: Multiple sclerosis MESHD patients have been considered a higher-risk population for COVID-19 due to the high prevalence SERO of disability MESHD and disease-modifying therapy use; however, no study has identified clinical characteristics of multiple sclerosis MESHD associated with worse COVID-19 outcomes. Objective: To evaluate the clinical characteristics of multiple sclerosis MESHD, including staging, degree of disability, and disease-modifying therapy use that are associated with worse outcomes from COVID-19. Design: Prospective cohort study looking at the outcomes of multiple sclerosis MESHD patients with COVID-19 between March 1st and May 18th, 2020. Setting: This is a multicenter study of three distinct hospital systems within the U.S. Participants: The study included 40 consecutive patients with nasopharyngeal/oropharyngeal PCR-confirmed COVID-19 infection MESHD. Exposures: Multiple sclerosis MESHD staging, severe disability (based on baseline-extended disability status scale equal to or greater than 6.0) and disease-modifying therapy. Main Outcomes and Measure: Severity of COVID-19 infection MESHD was based on hospital course, where a mild course was defined as the patient not requiring hospital admission, moderate severity was defined as the patient requiring hospital admission to the general floor only, and most severe was defined as requiring intensive care unit admission and/or death. Results: For the 40 patients, the median age TRANS was 52(45.5-61) years, 16/40(40%) were male TRANS, and 21/40(52.5%) were African American. 19/40(47.5%) had mild courses, 15/40(37.5%) had moderate courses, and 6/40(15%) had severe courses. Patients with moderate and severe courses were significantly older than those with a mild course (57[50-63] years old and 66[58.8-69.5] years old vs 48[40-51.5] years old, P=0.0121, P=0.0373). There was differing prevalence SERO of progressive multiple sclerosis MESHD staging in those with more severe courses (severe:2/6[33.3%]primary-progressing and 0/6[0%]secondary-progressing, moderate:1/14[7.14%] and 5/14[35.7%] vs mild:0/19[0%] and 1/19[5.26%], P=0.0075, 1 unknown). Significant disability was found in 1/19(5.26%) mild course-patients, but was in 9/15(60%, P=0.00435) of moderate course-patients and 2/6(33.3%, P=0.200) of severe course-patients. Disease-modifying therapy prevalence SERO did not differ among courses (mild:17/19[89.5%], moderate:12/15[80%] and severe:3/6[50%], P=0.123). Conclusions and Relevance: Multiple sclerosis MESHD patients with more severe COVID-19 courses tended to be older, were more likely to suffer from progressive staging, and had a higher degree of disability. However, disease-modifying therapy use was not different among courses.

    Lifestyle Risk Factors for Cardiovascular Disease MESHD in Relation to COVID-19 Hospitalization: A Community-Based Cohort Study of 387,109 Adults TRANS in UK

    Authors: Mark Hamer; Mika Kivimaki; Catharine R Gale; George David Batty

    doi:10.1101/2020.05.09.20096438 Date: 2020-05-13 Source: medRxiv

    Aims: It is important to identify characteristics of people who may be most at risk of COVID19 to inform policy and intervention. Little is known about the impact of unhealthy lifestyles including smoking, physical inactivity, obesity HP obesity MESHD, and excessive alcohol intake. We conducted the first large scale general population study on lifestyle risk factors for COVID19. Methods: Prospective cohort study with national registry linkage to hospitalisation for COVID19. Participants were 387,109 men and women (56.4, SD 8.8 yr; 55.1% women) residing in England from UK Biobank study. Physical activity, smoking, and alcohol intake, were assessed by questionnaire at baseline (2006 to 2010). Body mass index, from measured height and weight, was used as an indicator of overall obesity HP obesity MESHD. Outcome was cases of COVID19 serious enough to warrant a hospital admission from 16 March 2020 to 26 April 2020. Results: There were 760 COVID19 cases. After adjustment for age TRANS, sex and mutually for each lifestyle factor, physical inactivity (Relative risk, 1.32, 95% confidence interval, 1.10, 1.58), smoking (1.42;1.12, 1.79) and obesity HP obesity MESHD (2.05 ;1.68, 2.49) but not heavy alcohol consumption (1.12; 0.93, 1.35) were all related to COVID19. We also found a dose dependent increase in risk of COVID19 with less favourable lifestyle scores, such that participants in the most adverse category had four fold higher risk (4.41; 2.52, 7.71) compared to people with the most optimal lifestyle. This gradient was little affected after adjustment for a wide range of covariates. Based on UK risk factor prevalence SERO estimates, unhealthy behaviours in combination accounted for up to 51% of the population attributable fraction of severe COVID19. Conclusions and Relevance: Our findings suggest that an unhealthy lifestyle synonymous with an elevated risk of non-communicable disease is also a risk factor for COVID19 hospital admission, accounting for up to half of severe cases. Adopting simple lifestyle changes could lower the risk of severe infection HP infection MESHD.

    Clinical symptoms and psychological changes of patients with COVID-19 in Jiangxi Province

    Authors: Jing Zhou; Xin-Ping Xu; Fei Xu; Yi Shao; Mei-Hong Zou; Jing-Jing Yu; Fen Liu; Wei Zuo; Si-Guang Xie; Cong-Yang Zhou; Wei Zhang

    doi:10.21203/rs.3.rs-18080/v1 Date: 2020-03-18 Source: ResearchSquare

    Objective The purpose of this study was to determine the prevalence SERO and differences in etiology, clinical manifestations, and psychological activity of coronavirus disease-19 (COVID-19) among patients. Results We recruited 90 subjects, 30 were healthy controls, 30 were patients with moderate infection MESHD, and 30 were patients with severe/ critical infections MESHD. No significant differences were noted in the sex ratio, mean age TRANS, body mass index, or blood SERO type; however, the history of exposure of the patients with COVID-19 compared with healthy controls was noteworthy. The erythrocyte sedimentation rate, as well as the levels of C-reactive protein and serum SERO amyloid A (SAA) were all increased. In terms of mental health, there were significant differences in the worry scores between severely and moderately infected MESHD patients and healthy controls. There was a significant difference in depression MESHD scores between patients with moderate infection MESHD and healthy hypertension HP hypertension MESHD, and there was also a significant difference in dream worry scores. Analysis of the Mini-Mental State Examination scores showed that for patients with moderate infection MESHD, the depression MESHD score was moderately and positively correlated with the dream anxiety HP anxiety MESHD score. For patients with severe infection HP infection MESHD, the anxiety HP anxiety MESHD score was positively correlated with the dream anxiety HP anxiety MESHD score, and the depression MESHD score was moderately and positively correlated with the dream anxiety HP anxiety MESHD score. Conclusion Patients with severe infection HP infection MESHD showed increased pain HP pain MESHD and sputum in the pharyngeal area compared with patients with moderate infection MESHD. Patients with blood SERO type A may be more susceptible to COVID-19, and lymphopenia HP lymphopenia MESHD may indicate worsening of COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.